Amisulpride

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride Tablets (300mg) is a substituted benzamide atypical antipsychotic and dopamine D2/D3 receptor antagonist on the WHO Model List framework. At high doses (300-800 mg), it preferentially blocks postsynaptic dopamine D2 and D3 receptors in the limbic system, controlling positive symptoms of schizophrenia; at low doses (50 mg), it blocks presynaptic dopamine autoreceptors, increasing dopamine release to treat negative symptoms, dysthymia, and somatoform pain. Indicated for acute and chronic schizophrenia, dysthymic disorder, and management of chronic pain syndromes with psychosomatic components.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.